Dipna Pharmachem Ltd (DPL) — shareholding pattern, promoter holding, financials and share price
About Dipna Pharmachem Ltd (DPL)
Dipna Pharmachem Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as DPL and on the BSE under scrip code 543594. Its ISIN is INE0MC401013.
Incorporated in 2011, Dipna Pharmachem Ltd is in the business of Pharmaceutical Trading [1]
Dipna Pharmachem Limited focuses on the trading and distribution of pharmaceutical raw materials, specifically Active Pharmaceutical Ingredients (APIs) and intermediates.
The company has transitioned from private to public limited status, as marked by its recent incorporation in May 2022.
Listed peers in Pharmaceuticals: Desh Rakshak Aushdhalaya Ltd, Zenith Health Care Ltd, Starsource Multitrade Ltd, Ortin Global Ltd, Saroja Pharma Industries India Ltd, Beryl Drugs Ltd.
Valuation & Returns
10 Jul 2026At ₹5.76 a share on 10 Jul 2026, Dipna Pharmachem Ltd (DPL) was valued at a price-to-earnings ratio of 5.82x against an industry P/E of 36.41x and a price-to-book of 0.25x on a book value of ₹23.7 per share. Solomo computes return on equity of 4.22% and return on capital employed of 6.63% from filed results.
- P/E
- 5.82x
- Industry P/E
- 36.41x
- P/B
- 0.25x
- EPS (TTM)
- ₹0.41
- Book value / share
- ₹23.7
- ROE
- 4.22%
- ROCE
- 6.63%
- ROA
- 1.28%
- Debt / equity
- 0.21x
- Dividend yield
- 0%
- EBITDA margin
- 3.89%
- 52-week range
- ₹5.35 – ₹25.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Dipna Pharmachem Ltd (DPL) reported revenue of ₹129 crore, net profit of ₹3 crore and earnings per share of ₹1. That compares with revenue of ₹125 crore and net profit of ₹1 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2.05 crore and net profit ₹0.18 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 73 | 100 | 164 | 125 | 129 |
| Net profit (₹ cr) | 1 | 1 | 1 | 1 | 3 |
| EPS (₹) | 117 | 0.37 | 0.45 | 0.4 | 1 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 32.54% | 19.74% | -23.99% |
| Profit growth | 75.19% | -5.84% | -11.01% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 9.13% of Dipna Pharmachem Ltd (DPL). Market capitalisation was ₹15 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2022.
Largest disclosed public shareholders in Mar 2026: KAJAL ASHOK JAIN 4.28%, ASHOK DILIPKUMAR JAIN 4.26%, NAMITA HEMANT JAIN 4.21%, SIDDHARTH PODDAR 4.11%, TEENA KIRTI JAIN 3.75%, HEMANT NARESH JAIN HUF 3.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 9.13% | - | - | - | 90.87% |
| Sep 2025 | 9.98% | - | - | - | 90.02% |
| Mar 2025 | 9.98% | - | - | - | 90.02% |
| Sep 2024 | 9.98% | - | - | - | 90.02% |
| Mar 2024 | 9.98% | - | - | - | 90.02% |
| Sep 2023 | 57.19% | - | - | - | 42.81% |
| Mar 2023 | 66.56% | - | - | - | 33.44% |
| Sep 2022 | 66.56% | - | - | - | 33.44% |